Jane Street’s ADC Therapeutics ADCT Stock Holding History

Jane Street’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$533K	Sell	142,063 -57,701	-29%	-$227K	﹤0.01%	7904
2025 Q4	$705K	Sell	199,764 -288,104	-59%	-$1.17M	﹤0.01%	6942
2025 Q3	$1.95M	Buy	+487,868	New	+$1.54M	﹤0.01%	4985
2024 Q4	–	Sell	-53,126	Closed	-$167K	–	9279
2024 Q3	$167K	Buy	53,126 +38,859	+272%	+$123K	﹤0.01%	8754
2024 Q2	$45.1K	Sell	14,267 -12,717	-47%	-$50.5K	﹤0.01%	8934
2024 Q1	$121K	Sell	26,984 -74,276	-73%	-$274K	﹤0.01%	8454
2023 Q4	$168K	Buy	+101,260	New	+$93.4K	﹤0.01%	8333
2023 Q3	–	Sell	-16,467	Closed	-$35.4K	–	8534
2023 Q2	$35.4K	Sell	16,467 -9,117	-36%	-$20.5K	﹤0.01%	8280
2023 Q1	$49.9K	Buy	+25,584	New	+$94.4K	﹤0.01%	8453

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's ADCT Position: Q1 2026 in Review

Jane Street reduced its ADC Therapeutics (ADCT) stake by 29% in Q1 2026, selling an estimated $227K and leaving 142,063 shares worth $533K. The position accounts for ﹤0.01% of the portfolio, ranked #7904.

Jane Street first reported a position in ADCT in Q1 2023 and has held it in 9 quarters since. The position peaked at $1.95M in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Jane Street held 142,063 shares of ADC Therapeutics worth $533K as of Q1 2026.
Jane Street sold 57,701 ADC Therapeutics shares in Q1 2026, an estimated $227K.
ADC Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7904 holding.
Jane Street first reported a position in ADC Therapeutics in Q1 2023 and has held it in 9 quarters since.
Jane Street's ADC Therapeutics position peaked at $1.95M in Q3 2025.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.